The study, which is evaluating the company’s immunotherapy eftilagimod alfa in combination with radiotherapy and MSD's KEYTRUDA (pembrolizumab) for resectable soft tissue sarcoma, significantly exceeded its prespecified pathologic response target. …
Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity
November 13, 2025 Australian Biotech
Latest Video
New Stories
-
Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity
November 13, 2025 - - Australian Biotech -
PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal
November 13, 2025 - - Australian Biotech -
New gene discoveries improve diagnosis of inherited heart disease
November 13, 2025 - - Australian Biotech -
Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial
November 13, 2025 - - Australian Biotech -
Australia joins global WHO task force to tackle antimicrobial resistance
November 13, 2025 - - Latest News -
New post-market review workplan focuses on real-world data and patient outcomes
November 13, 2025 - - Latest News -
Government adds new first-line treatment to the PBS for deadly blood cancer
November 13, 2025 -